Laboratoire Druide Inc., a Canadian manufacturer of over-the-counter drug products including sunscreens, skin protectants, and hand sanitizers, failed to conduct required identity testing on incoming components and did not establish the reliability of supplier test analyses at appropriate intervals, violating Current Good Manufacturing Practice (CGMP) regulations. The firm relied on suppliers' certificates of analysis without adequate verification and failed to perform required limit testing on glycerin shipments to detect contamination by diethylene glycol and ethylene glycol, resulting in adulterated drug products. These significant violations of 21 CFR parts 210 and 211 were documented during an FDA inspection conducted February 10-14, 2025, and the firm's March 6, 2025 response was reviewed in detail before the warning was issued.